Work

Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.4514

Authors: Charles G. Drake, David F. McDermott, Mario Sznol, Toni K. Choueiri, Harriet M. Kluger, John D. Powderly, David C. Smith, Vindira Sankar, Andres A. Gutierrez, Jon M. Wigginton, Georgia Kollia, Ashok Kumar Gupta, Michael B. Atkins

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Dana-Farber Cancer Institute, Yale Cancer Center, Yale University, Carolina BioOncology Institute, U-M Rogel Cancer Center, Bristol-Myers Squibb (United States), Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2470779388

Cites:

Cited by: 55

Related to: 10